Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kathy Y Liu

Showing results (1-10 of 58) with videos related to

Pageof 6
Sort By:
The British Journal of Psychiatry : the Journal of Mental Science|February 3, 2017
Personality disorders and suicide in ChinaKathy Y Liu
The British Journal of Psychiatry : the Journal of Mental Science|March 21, 2018
Why has adult hippocampal neurogenesis had so little impact on psychiatry?Kathy Y Liu, Robert Howard
Nature Reviews. Neurology|December 1, 2019
Questions EMERGE as Biogen claims aducanumab turnaroundRobert Howard, Kathy Y Liu
BMJ (Clinical Research Ed.)|April 5, 2023
Air pollution and dementiaAndrew Sommerlad, Kathy Y Liu
Nature Reviews. Neurology|September 18, 2021
Can we learn lessons from the FDA's approval of aducanumab?Kathy Y Liu, Robert Howard
The Lancet. Neurology|August 14, 2021
Pimavanserin and dementia-related psychosis: can HARMONY prevail?Kathy Y Liu, Robert Howard
International Psychogeriatrics|June 3, 2021
Frailty and dementia: what can the body tell us about the brain?Kathy Y Liu, Naaheed Mukadam
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 27, 2025
Avoiding causal fraud in the evaluation of clinical benefits of treatments for Alzheimer's diseaseKathy Y Liu, Stephen Senn, Robert Howard
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 26, 2022
How can secondary dementia prevention trials of Alzheimer's disease be clinically meaningful?Kathy Y Liu, Madhav Thambisetty, Robert Howard
The Journal of Prevention of Alzheimer'S Disease|May 7, 2026
Clarity AD open-label extension data do not robustly confirm disease course modification by lecanemab in ApoE<sub>4</sub> heterozygotes and non-carriersJemma Hazan, Kathy Y Liu, Robert Howard
Pageof 6

Showing results (1-10 of 58) with videos related to

Sort By:
Pageof 6
The British Journal of Psychiatry : the Journal of Mental Science|February 3, 2017
Personality disorders and suicide in ChinaKathy Y Liu
The British Journal of Psychiatry : the Journal of Mental Science|March 21, 2018
Why has adult hippocampal neurogenesis had so little impact on psychiatry?Kathy Y Liu, Robert Howard
Nature Reviews. Neurology|December 1, 2019
Questions EMERGE as Biogen claims aducanumab turnaroundRobert Howard, Kathy Y Liu
BMJ (Clinical Research Ed.)|April 5, 2023
Air pollution and dementiaAndrew Sommerlad, Kathy Y Liu
Nature Reviews. Neurology|September 18, 2021
Can we learn lessons from the FDA's approval of aducanumab?Kathy Y Liu, Robert Howard
The Lancet. Neurology|August 14, 2021
Pimavanserin and dementia-related psychosis: can HARMONY prevail?Kathy Y Liu, Robert Howard
International Psychogeriatrics|June 3, 2021
Frailty and dementia: what can the body tell us about the brain?Kathy Y Liu, Naaheed Mukadam
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 27, 2025
Avoiding causal fraud in the evaluation of clinical benefits of treatments for Alzheimer's diseaseKathy Y Liu, Stephen Senn, Robert Howard
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 26, 2022
How can secondary dementia prevention trials of Alzheimer's disease be clinically meaningful?Kathy Y Liu, Madhav Thambisetty, Robert Howard
The Journal of Prevention of Alzheimer'S Disease|May 7, 2026
Clarity AD open-label extension data do not robustly confirm disease course modification by lecanemab in ApoE<sub>4</sub> heterozygotes and non-carriersJemma Hazan, Kathy Y Liu, Robert Howard
Pageof 6